Kyue Yim Lee

Ms. Kyue Yim Lee

National Cancer Center, Gyeonggi-do, South Korea
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
SKSu-Hyun Kim
Su-Hyun Kim
WKWoojun Kim
Woojun Kim
SHSo-Young Huh
So-Young Huh
Kyue Yim LeeKyue Yim Lee
Kyue Yim Lee
IJIn Ja Jung
In Ja Jung
HKHo Jin Kim
Ho Jin Kim
Kim SH, et al. J Clin Neurol. 2013 Jan;9(1):36-42. http://dx.doi.org/10.3988/jcn.2013.9.1.36

1 January 2010 in Journal of Biomedicine and Biotechnology
Verified
Journal Article
Open access
PDF file
Kyue Yim LeeKyue Yim Lee
Kyue Yim Lee
HKHyungu Kang
Hyungu Kang
SRSung Ho Ryu
Sung Ho Ryu
DLDong Soo Lee
Dong Soo Lee
JLJung Hwan Lee
Jung Hwan Lee
SKSoonhag Kim
Soonhag Kim
Chemically modified nucleotides have been developed and applied into SELEX procedure to find a novel type of aptamers to fit with targets of interest. In this study, we directly performed chemical modification of 5-(N-benzylcarboxyamide)-2′-deoxyuridine (called 5-BzdU) in the AS1411 aptamer, which binds to the nucleolin protein expressed in cancer cells. Forty-seven compounds of AS1411-containing Cy3-labeled 5-BzdU (called Cy3-(5-BzdU)-modified-AS1411) were synthesized by randomly substituting thymidines one to twelve in AS1411 with Cy3-labeled 5-BzdU. Both statistically quantified fluorescence measurements and confocal imaging analysis demonstrated at least three potential compounds of interest: number 12, 29 and 41 that significantly increased the targeting affinity to cancer cells but no significant activity from normal healthy cells. These results suggest that the position and number of substituents in AS1411 are critical parameters to improve the aptamer function. In this study, we demonstrated that chemical modification of the existing aptamers enhanced the binding and targeting affinity to targets of interest without additional SELEX procedures.

1 December 2011
Verified
Journal Article
Closed access
Kyue Yim LeeKyue Yim Lee
Kyue Yim Lee
YKYoun-Jae Kim
Youn-Jae Kim
HYHeon Yoo
Heon Yoo
SLSeung Hoon Lee
Seung Hoon Lee
JPJong Bae Park
Jong Bae Park
HKHo Jin Kim
Ho Jin Kim

18 June 2020 in EPMA Journal
Verified
Journal Article
Closed access
PDF file
JIJi Hye Im
Ji Hye Im
BYByong Chul Yoo
Byong Chul Yoo
JLJun Hwa Lee
Jun Hwa Lee
KKKyung-Hee Kim
Kyung-Hee Kim
TKTae Hoon Kim
Tae Hoon Kim
HGHo-Shin Gwak
Ho-Shin Gwak

24 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Kyue Yim LeeKyue Yim Lee
Kyue Yim Lee
JIJi Hye Im
Ji Hye Im
WLWeiwei Lin
Weiwei Lin
HGHo-Shin Gwak
Ho-Shin Gwak
JKJong Heon Kim
Jong Heon Kim
CLChangjin Lee
Changjin Lee
Leptomeningeal metastasis (LM) has a poor prognosis and is difficult to diagnose and predict the response of treatment. In this study, we suggested that the monitoring of changes in the concentration of extracellular vesicles in cerebrospinal fluid could help diagnose or predict outcomes for LM. We measured nanoparticles in 472 human cerebrospinal fluid (CSF) from patients including LM with both Dynamic Light Scattering (DLS) and Nanoparticle Tracking Analysis (NTA) after two-step centrifugations. NTA revealed that the concentration of CSF nanoparticles was significantly increased in LM compared to other groups (2.80 × 108 /mL vs. 1.49 × 108 /mL, p < 0.01). Changes in NTA-measured nanoparticles concentration after intra-CSF chemotherapy were further examined in 33 non-small cell lung cancer patients with LM. Overall survival was longer for patients with increased EV than the others (442 vs. 165 days, p < 0.001). Markers of extracellular vesicles (CD9/CD63/CD81) significantly decreased in the EV-decreased group. MicroRNA-21 expression decreased in this favorable prognostic group, whereas it increased in the EV-decreased group. In conclusion, the elevated concentration of extracellular vesicles in cerebrospinal fluid in patients with LM may be a predictive marker for survival duration. Moreover, EV changes combined with microRNA-21 might be a biomarker for monitoring the efficacy of intracranial chemotherapy of LM in non-small cell lung cancer patients.

8 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Kyue Yim LeeKyue Yim Lee
Kyue Yim Lee
YSYoona Seo
Yoona Seo
JIJi Hye Im
Ji Hye Im
JRJiho Rhim
Jiho Rhim
WBWoosun Baek
Woosun Baek
JKJong Heon Kim
Jong Heon Kim
Leptomeningeal metastasis (LM) is a fatal and rare complication of cancer in which the cancer spreads via the cerebrospinal fluid (CSF). At present, there is no definitive treatment or diagnosis for this deleterious disease. In this study, we systemically and quantitatively investigated biased expression of key small non-coding RNA (smRNA) subpopulations from LM CSF extracellular vesicles (EVs) via a unique smRNA sequencing method. The analyzed subpopulations included microRNA (miRNA), Piwi-interacting RNA (piRNA), Y RNA, small nuclear RNA (snRNA), small nucleolar RNAs (snoRNA), vault RNA (vtRNA), novel miRNA, etc. Here, among identified miRNAs, miR-21, which was already known to play an essential oncogenic role in tumorigenesis, was thoroughly investigated via systemic biochemical, miR-21 sensor, and physiological cell-based approaches, with the goal of confirming its functionality and potential as a biomarker for the pathogenesis and diagnosis of LM. We herein uncovered LM CSF extravesicular smRNAs that may be associated with LM-related complications and elucidated plausible pathways that may mechanistically contribute to LM progression. In sum, the analyzed smRNA subpopulations will be useful as targets for the development of therapeutic and diagnostic strategies for LM and LM-related complications.